Beam Therapeutics sues former scientist and Chinese biotech over alleged gene-editing IP theft

The base-editing company Beam Therapeutics has initiated legal action against a former employee, the Chinese biotech company Yoltech, and a VC-backed start-up called Serapha, alleging misappropriation of trade secrets and intellectual property related to its gene-editing platform. According to reporting by STAT News, Beam claims the scientist in question used proprietary information obtained during their employment to help establish Yoltech, which subsequently entered into agreements with venture capital investors.

Beam Therapeutics, founded in part on technology developed from the laboratory of David Liu at the Broad Institute of MIT and Harvard, is one of a small number of companies with advanced base-editing capabilities — techniques that allow single-letter changes to DNA without introducing double-strand breaks. The company has active programmes in sickle cell disease, leukaemia, and other conditions.

The case illustrates the intensifying competition in the gene-editing sector between US and China-based biotechnology companies, and raises questions about how proprietary platform technologies are protected as the field globalises. The lawsuit was filed in a US federal court; the defendants had not publicly responded to the allegations at the time of publication.

This summary is based on reporting by STAT News published on 29 September 2026. The allegations are untested in court; Evagene presents the filing as reported, not as established fact.